Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa

Provini, Lauren; Stellar, Judith J.; Stetzer, Molly; Nguyen, Phuong D.; Jen, Melinda

doi:10.1111/pde.13775

Cited by 16 publications

(15 citation statements)

References 7 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases where the pretest probability of IBD is high, a normal FCP value is unlikely to prevent an endoscopy. For example, in a child with hidradenitis suppurativa, low albumin and perianal fistula, a normal FCP test did not preclude further investigation, and an endoscopy and biopsy were subsequently performed to exclude IBD 24 . In such cases, the value of FCP is debatable.…”

Section: Faecal Calprotectin Testing In Dermatologymentioning

confidence: 99%

Faecal calprotectin in dermatology practice

Premjeyanth

Shipman

2020

Clin Exp Dermatol

View full text Add to dashboard Cite

Summary Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the bowel with two primary subtypes: Crohn disease and ulcerative colitis. Extraintestinal manifestations are common in IBD and, after musculoskeletal involvement, dermatological lesions are the most common. Currently, colonoscopy and biopsy are the most definitive tests for a diagnosis of IBD. However, in the past decade, faecal markers have emerged as new diagnostic tools to detect and monitor intestinal inflammation, and faecal calprotectin (FCP) in particular has gained popularity owing to its high sensitivity and specificity for detection of organic bowel disease. This review aims to explore whether there is a role for FCP measurement when encountering cutaneous manifestations associated with IBD.

show abstract

Section: Faecal Calprotectin Testing In Dermatologymentioning

confidence: 99%

Faecal calprotectin in dermatology practice

Premjeyanth

Shipman

2020

Clin Exp Dermatol

View full text Add to dashboard Cite

show abstract

“…In total, 15 studies met eligibility criteria and were used for data collection and analysis of 26 patients. 13 - 27 The analysis of the level of evidence showed that 6 studies (40%) had a level of evidence of 4 and 9 studies (60%) had a level of evidence of 5. Overall, patients were between 6 and 17 years of age (mean: 15 years ± 2.3) at presentation and initiation of biologics.…”

Section: Resultsmentioning

confidence: 99%

“…6 However, this study reviewed mostly adult patients and did not report pediatric data separately, 6 whereas our review included only pediatric studies. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] In addition to anti-TNF-α , anti-IL-1 may be effective against HS as elevated TNF-α and IL-1β levels have been detected in HS lesions. 28 IL-1β and TNF-α levels in HS lesions were elevated 31-fold and 5-fold, compared to healthy skin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background: There is currently at least 1 biologic (adalimumab) approved in North America for treatment of Hidradenitis Suppurativa in the pediatric population. However, no reviews or clinical trials have specifically analyzed the effectiveness and safety data of biologic use in this population. The objective of this systematic review is to identify and summarize the outcomes of biologic therapy in pediatric patients with HS. Methods: MEDLINE and EMBASE databases were used to conduct the search on Sept 18, 2020. Results: The 15 included studies consisted of 26 patients, with the mean age of 15 ± 2.3 years. Females accounted for 53.8% ( n = 14/26) of cases. The mean duration of HS prior to biologic initiation was 3.5 ± 2.9 years, with the majority having Hurley Stage II. The 26 patients received 34 biologics in total: 85.3% treated with TNF alpha inhibitors (adalimumab n = 17, infliximab n = 10, etanercept n = 1, unspecified n = 1), 5.9% with IL-12/23 inhibitors (ustekinumab n = 2), 5.9% with IL-1 inhibitors (i.e., anakinra n = 2) and 2.9% received IL-23 inhibitors (i.e., guselkumab n = 1) biologics. Of the 26 patients, 23.1% ( n = 6/26) experienced complete resolution (CR), 73.1% ( n = 19/26) experienced partial resolution (PR), and 3.8% ( n = 1/26) had no resolution outcomes reported. The time to resolution of HS lesions after biologic initiation ranged from 10 days to 11.5 months (mean: 5.1 months). No adverse events were reported in the studies. Conclusion: Although anti-TNF alpha were the most common biologics used for HS in pediatric cases, large-scale trials specific to pediatric patients with HS are needed to confirm these findings.

show abstract

“…Interestingly, according to the authors’ experience, the long-term efficacy of secukinumab may not be influenced by the administration or not of induction [ 245 ]. A successful combination of hyperbaric oxygen therapy (6 days per week for 6 weeks) and high-dose ustekinumab (90 mg every 4 weeks) was described in a pediatric obese female HS patient [ 246 ].…”

Section: (New Medical) Therapeutical Approaches In Hsmentioning

confidence: 99%

Insights into the Pathogenesis of HS and Therapeutical Approaches

et al. 2021

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a debilitating, chronic, (auto)inflammatory disease primarily affecting apocrine gland-rich areas of the body. Although pathogenic mechanisms responsible for HS have not yet been fully elucidated, it is a multifactorial process whose main target is the terminal follicle. The role of the inflammatory process (and consequently of cytokine milieu) and of several other factors (genetics, lifestyle, hormonal status, microbiome, innate and adaptive immune systems) involved in HS pathogenesis has been investigated (and often defined) over the years with a view to transferring research results from bench to bedside and describing a unique and universally accepted pathogenetic model. This review will update readers on recent advances in our understanding of HS pathogenesis and novel (potential) medical therapies for patients with moderate-to-severe HS.

show abstract

Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa

Cited by 16 publications

References 7 publications

Faecal calprotectin in dermatology practice

Faecal calprotectin in dermatology practice

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review

Insights into the Pathogenesis of HS and Therapeutical Approaches

Contact Info

Product

Resources

About